Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.
Also called NCT01106131
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 253 participants
- Registry
-
NCT01106131
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01106131. Randomized; triple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- CKD-501 0.5mg
- Intervention (Drug)
- Pioglitazone 15mg
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct01106131- Content hash
902dd51bbc79913bf2b74b251492cdab437b1d98e5aa4f9503b3dcedcabedf52